MM-151 + trametinib

MM-151 + trametinib is a combination investigational therapy of MM-151, an anti-EGFR monoclonal antibody, and trametinib, a selective MEK1/2 inhibitor. MM-151 targets and blocks multiple epitopes of the epidermal growth factor receptor (EGFR), inhibiting ligand-induced activation and downstream cancer-promoting signaling. Trametinib inhibits MEK1 and MEK2 enzymes in the MAPK/ERK pathway, preventing cancer cell proliferation driven by RAS-RAF-MEK-ERK signaling. This combination aims to overcome resistance mechanisms in tumors, particularly those reliant on EGFR and MAPK pathway activation, including certain colorectal cancers and other advanced solid tumors.

Other names

trametinibMM-151MM151MM 151